AINEWS
Private deal, not a public market cap. BlackRock, UAE funds including Abu Dhabi's MGX, and existing backers are deciding who writes the check, with no lead investor named yet.
OpenAI is pitching investors on a roughly $30 billion round at a pre-money valuation of about $1.4 trillion, with the lab itself setting the price rather than negotiating it. There is no lead investor in place. The pool of buyers is a short list: sovereign wealth funds, BlackRock.
OpenAI is in talks with UAE funds and BlackRock for the round, terms subject to change, per a Bloomberg report carried by Business Standard. OpenAI and BlackRock declined to comment. MGX, an Abu Dhabi-based fund, did not respond. The reported participants include MGX, Thrive Capital, Andreessen Horowitz, and the University of California endowment. The syndicate is the deal.
In venture, the lead investor normally sets the price by putting in the most money and organizing the rest. OpenAI is reportedly skipping that step. The lab is presenting the $1.4 trillion figure to investors as a set price, a structure more common in late-stage private placements than in startup rounds. The company, not the market, is now pricing the next leg of the AI buildout.
This is a different transaction from the $122 billion round OpenAI closed in March at an $852 billion valuation. Six months ago, a group of investors led the financing and the number was negotiated. Now the lab is setting the number and assembling the buyers. BlackRock is in talks to participate. MGX, which raised close to $50 billion earlier this year to accelerate AI infrastructure spending, is discussing up to $10 billion in aggregate participation alongside other UAE funds. The University of California endowment, Thrive, and Andreessen Horowitz have also discussed joining. Together they are the roster of buyers that can absorb a $30 billion check without rewriting their own underwriting rules.
More capital flowing into frontier AI is closer to project finance than venture finance: a utility-scale buildout underwritten by pools of permanent capital that do not need a quarterly return. That kind of money makes it easier to pay for the compute, data centers, and grid capacity the next generation of AI requires, and gives the lab room for the long-cycle research public markets do not finance well. It also widens the gap between labs that can clear this bar and labs that cannot. The 2026 AI race is increasingly a question of who can fund multi-year buildouts at scale, and the answer is now a short list of institutions, not a market.
The same structure concentrates both capital and decision-making. A private company setting its own price, with a sovereign wealth fund underwriting a US AI lab, and a deal whose public terms are thin, leaves the price of admission as a conversation between a small group of institutions and a small group of executives, with no public filing to inspect. OpenAI has pushed its IPO plans to at least next year, citing a focus on AI safety. The longer the company stays private at this size, the longer the public terms stay short. That opacity is the price of patient capital, and it is the part the dollar number does not show.
The round has not closed, and the terms could change. The $1.4 trillion figure is a reported pre-money target, not a settled valuation. Several named participants, including MGX, Andreessen Horowitz, and the University of California, did not respond to requests for comment. Before any money moves, the structure shows that the financing of frontier AI has settled into a small set of relationships, with the lab on the selling side of the table. The next milestone to watch is whether a lead investor surfaces, or whether the round closes as a fully lab-priced syndication.